Carbone, Federico
Djamshidian, Atbin
Seppi, Klaus
Poewe, Werner
Article History
First Online: 31 August 2019
Compliance with Ethical Standards
:
: No sources of funding were used to conduct this study or prepare this manuscript. Open access funding provided by University of Innsbruck and Medical University of Innsbruck.
: Federico Carbone has no conflicts of interest that are directly relevant to the content of this review. Atbin Djamshidian has received consulting fees from Abbvie and Grünenthal. Klaus Seppi has received fees from Teva, UCB, Lundbeck, AOP Orphan Pharmaceutical AG, Roche, Grünenthal and Abbvie; honoraria and research grants from the International Parkinson and Movement Disorder Society; and research grants from the FWF Austrian Science Fund and Micheal J. Fox Foundation outside of the submitted work. Werner Poewe has received consulting fees from Britannia Pharmaceuticals for planning and implementation of the TOLEDO study; consulting fees from Grünenthal in relation to apomorphine educational activities; and lecture fees from Britannia Pharmaceuticals and Grünenthal related to symposia on the TOLEDO study and for apomorphine educational activities.